PRINCETON, N.J.--Chiromics LLC today announced a strategic research alliance with Bristol-Myers Squibb Company (NYSE:BMY) which includes grants of non-exclusive license for use of Chiromics' chemical compound library, exclusive license to a proprietary chemical compound collection, and a screening collaboration to discover and optimize novel classes of small molecules against multiple therapeutic targets.
Chiromics' compound collections are assembled using Chiromics' core chemical technology referred to as "cascade catalysis." This technology was invented in the MacMillan Laboratories at Princeton University. Cascade catalysis allows for the creation of "accessible complexity," a diverse collection of molecules that is more complex than and differentiated from currently existing small molecule collections, while retaining drug-like properties, the ability to develop structure-activity relationships and ease of re-synthesis.
The synergistic combination of Chiromics' chemical compound collection of accessible complexity, and ChalisTM, Chiromics' exclusive hit recognition algorithm for affinity selection, enables the identification of new lead molecules that is complementary to conventional high throughput screening processes.
Chiromics' founder David MacMillan, Ph.D., James S. McDonnell Distinguished University Professor of Chemistry and Chairman of the Chemistry Department at Princeton University, stated, "We are delighted that Bristol-Myers Squibb has chosen Chiromics as a drug discovery partner based on their proven commitment to innovation and reputation as a strong collaborator with biotech companies. This collaboration further authenticates that Chiromics' chemical technology and discovery platform is a unique gateway to a new set of small molecules for drug discovery."
About Chiromics LLC
Chiromics LLC is a drug discovery company that designs and synthesizes broadly diverse chemical compound libraries, using a patented "cascade catalysis" technology that produces drug-like molecules with a stereochemically defined framework. The novel structures and accessible complexity of these compounds expands the access to important disease targets and accelerates the hit-to-lead time for identification of novel drugs.
Formed in 2009 and based in Princeton, N.J., Chiromics has established collaborations with leading biotech and pharmaceutical companies for licensing and screening of its libraries against a broad array of disease targets. For more information, visit www.chiromics.com.